Débora Claramunt-Taberner

Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?

Débora Claramunt-Taberner, Aurélia Bertholet‐Thomas, Marie-Christine Carlier et al. · Pediatric Nephrology · 2018 · 34 citations

Medicine, Endocrinology, Oncology +17

Marked alterations in the structure, dynamics and maturation of growth plate likely explain growth retardation and bone deformities of young Hyp mice

Rocío Fuente, Helena Gil‐Peña, Débora Claramunt-Taberner et al. · Bone · 2018 · 31 citations · Full text

Medicine, Cell Biology, Developmental Biology +17

Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment

Aurélia Bertholet‐Thomas, Débora Claramunt-Taberner, Ségolène Gaillard et al. · Pediatric Nephrology · 2018 · 27 citations

Medicine, Nephrology, Pediatrics +14

Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction

Débora Claramunt-Taberner, Sacha Flammier, Ségolène Gaillard et al. · Nephrology Dialysis Transplantation · 2017 · 26 citations · Full text

Medicine, Nephrology, Pharmacology +14

MAPK inhibition and growth hormone: a promising therapy in XLH

Rocío Fuente, Helena Gil‐Peña, Débora Claramunt-Taberner et al. · The FASEB Journal · 2019 · 18 citations · Full text

Medicine, Endocrinology, Pediatrics +17